8:00 am Registration & Morning Coffee

8:50 am Chairperson’s Opening Remarks

Developing Conformation-Specific & Conformation Agnostic Therapeutics to Target Protein Misfolding & Aggregation

9:00 am Small Molecule Inhibitors of a Common Conformational Morphology Identified in Intrinsically Disordered Proteins

  • Marcia Taylor VP Research & Neurodegeneration Alliance Manager, Treventis


  • Common Conformational Morphology (CCM) acts as an in silico crystal structure  for IDPs
  • Hit identification has been performed for alpha synuclein, amylin, amyloid beta, and tau
  • Demonstrated dose dependent decrease in oligomeric species of amyloid beta and tau 

9:30 am Amyloid Removal Therapy for Systemic Amyloidosis


• Generation of amyloid selective antibodies from human immune memory repertoires
• Lead selection and PoC studies with focus on assays with high translational value
• Modeling treatment response to support clinical trial design

10:00 am Rational Design of Conformation-Specific Antibodies Targeting Protein Aggregates

  • Michele Vendruscolo Professor & CSO, Cambridge University Centre for Misfolding Diseases & Wren Therapeutics


• Discussing why protein oligomers are challenging targets for antibody discovery
• Presenting a method of antibody discovery for these targets
• Exploring how these antibodies can be used for diagnostics and therapeutics

10:30 am Speed Networking & Morning Refreshments

Identifying Novel Therapeutics Using Innovative Drug Discovery Approaches

11:30 am A Network Kinetics Drug Discovery Strategy for Targeting Protein Aggregation


• Protein aggregation is a kinetics process, therefore kinetics readouts are needed
• Unravelling the mechanism of protein aggregation using chemical kinetics at a detailed microscopic level provides with an exceptional opportunity of a controlled intervention and consequently leads to a selective targeting of the toxic species
• The quantitative and predictive power of chemical kinetics allows for a systematic optimization of therapeutics molecules with desired properties

Optimizing Preclinical Models & Technologies for Robust Translation into the Clinic

12:00 pm Reviewing Tau as a Therapeutic Strategy for Neurodegenerative Diseases

  • Suchira Bose Research Advisor & Head of Molecular Pathology, Neuroscience, Eli Lilly


• Tau normal function and dysfunction in Alzheimer’s disease and other neurodegenerative diseases
• Tau aggregation: biochemical and structural insights
• New insights in tau dysfunction: developing models to study ‘prion-like’ propagation

12:30 pm Discovery & Clinical Translation of a Small-Molecule Inhibitor of α-Synuclein Toxicity


• Using a yeast-to-human phenotypic screening platform we recently discovered that small molecule inhibitors of stearoyl-coA-desaturase (SCD) potently protect cells from α-synuclein toxicity
• Preclinical data confirmed that reduction of fatty-acid desaturation is correlated with protection, providing a translational pharmacodynamic marker that can be used in animals and human studies
• Focusing on the preclinical discovery and recent Phase Ia human clinical data from our lead SCD inhibitor, YTX-7739

1:00 pm Networking Lunch

2:00 pm Using Single Particle Detection Technologies to Quantify Pathological Tau in Extracellular Vesicles & Biofluids


• Outlining methods development
• Discussing the value of exosome capture in distinguishing AD from control
• Comparing CSF and plasma

2:30 pm Discussing ALZ-801 – A Phase 3 Ready Conformational Modifier with Disease Modifying for Alzheimer’s Disease


    • Presenting a small molecule modifier of protein misfolding through a novel “enveloping MOA”
    • Discussing how these small molecule modifiers represent a promising new class of agents for neurodegenerative disease

Harnessing Cross-Learnings to Expand Therapeutic Portfolios into Novel Disease Indications

3:00 pm Cross-Learnings from Mechanisms of Action Underlying Protein Conformational Disorders


  • How to evaluate the safety and tolerability of novel protein misfolding  therapeutics as assessed through clinical development
  • How can the commonalities in underlying molecular pathology be used to inform the development of new treatment options for protein-misfolding diseases? 
  • How can you leverage a clinical developmental strategy to address a range of diseases caused by protein misfolding for which no approved disease-modifying  treatments currently exist? 

3:30 pm Afternoon Refreshments

4:00 pm Interactive Roundtable Discussions


Our breakout roundtables will allow you to have more intimate and open discussions on some of the hottest topics and key areas of debate. Drive your own learning, crowd-source ideas and get inspired. Immerse yourself in the following discussions:

  1. How to discover novel targets for next-generation therapeutics for protein conformational diseases?
  2. How to expand the applications of misfolded protein therapeutics beyond neurodegeneration?
  3. How to strategically accelerate misfolded protein research by leveraging the expertise, tools and resources at our disposal?

5:00 pm Chairperson’s Closing Remarks & End of Day One